fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Second Half Kicks Off With Equities Pulling Back During This Holiday-Shortened Week – $ADT $AI $AZTR $INM $LTRN $META TSLA Rise!

By John F. Heerdink, Jr.


Quote of the Day:  “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill


Happy Saturday!

I hope that you had a wonderful holiday-shortened week and kicked off the second half with a bit of gusto. 

As for the broad markets this week, stocks moved significantly lower over the course week as a number of global economic growth & US Fed raising interest rate concerns seemed to dominate the non-vacationing investors Psyche that were left at the helm. The S&P 500 closed at 4,398.95 (-1.2%) for the week and is now up 14.6% YTD as 1o out of the 11 sectors closed in the red this week with the real estate sector up .2% leading all and the health care sector off 2.9%, the materials sector off 2%, & the heavily weighted information technology sector off 1.5% binging up the rear.

The Dow 30 closed back below the 34k level at 33,734.80 giving back the 2% gained last week and is now up just 1.8% YTD.  The Walt Disney Company (DIS) closed at $88.64, -.35% over the last 5-days as the politically charged DeSantis ‘woke-feud’ wages on in Florida. Nike (NKE) closed at $1104.46, -7.86% over the last 5-days after last week’s quarterly earnings miss and somewhat dismal view surfaced. 

The Nasdaq closed at 13,660.70 (-.9%) and is now up an amazing 30.5% YTD.  The ‘Magnificent Seven’ performed as follows over the last 5-days: which includes Apple (AAPL, $190.68, +.57% over the last 5-days, +46.76% YTD), Alphabet (GOOGL $119.48, +.32% over the last 5-days,  +35.42% YTD, GOOG, $120.14, +.11%, +35.40% YTD), Microsoft (MSFT, $337.22, +.65% over the last 5-days, +40.61% YTD), Amazon (AMZN, $129.78, +1.47% over last 5-days, +54.50% YTD), Meta (META,$290.53, +3.20%, +141.42% YTD) as it introduced their new Twitter-like social media offering Threads to much fanfare and to the reported chagrin of Elon Musk, Tesla (TSLA, $274.43, +6.57% over last 5-days, +12.79% YTD) after releasing a report that confirmed Q2/2023 marked the 5th period in a row that Tesla reported a higher level of vehicles produced compared to deliveries coming in with 466,140 deliveries & production of 479,700 vehicles, and Nvidia (NVDA, $425.03, +4.12% over the last 5-days, +190.84% YTD). This so-called group accounts for ~84% of the Nasdaq 100’s ~$4T growth in market cap YTD. Netflix (NFLX) also rebounded this week to close at $438.19, +2.30% over the last 5-days, +48.57% YTD. C3 AI (NYSE: AI) over the last 5-days closed at $39.25, +9.33% , & 250.76% YTD.  

The small caps on the Russell 2000 closed at 1,864.66 (-1.3%) for the week & is now up 5.9% YTD. The MicroCaps also moved higher this week as the iShares Micro-Cap ETF (IWC) closed at $108.65,-.49% this week & is now up only .76% YTD.  

The macroeconomic schedule provided another group of interesting reports. On Monday, the ISM Manufacturing Index report that showed further into contraction in June coming in at 46% off nearly a point. On Wednesday, the Factory orders repot showed a .3% M/M rise in May but approximately half the rise that was expected, while shipments of manufactured goods rose .3% M/M. On Thursday, Private sector hiring was reported to have risen by 497k in June, while jobs in the goods-producing sector rose by 124k & jobs in the service-providing sector jumped by 373k as small – medium businesses led the way with a significant gain vs. an 8k drop at large businesses. The Initial jobless claims report for the week ending July 1 rose by 12k to 248k, while Continuing jobless claims for the week ending June 24 fell by 13k to 1.72M. The JOLTS or Job Openings report showed a total of 9.824M in May. Beyond the job data the schedule produced the May Trade Balance Report that confirmed a narrowing in the trade deficit to $69B. The ISM Non-Manufacturing Index report for June came in higher at 53.9%. The Weekly EIA Crude Oil Inventories report confirmed a 1.51M barrel draw. On Friday, the Nonfarm payrolls report showed a 209k rise in June that missed expectations, while the average hourly earnings rose .4% greater than expected.

The SPDR S&P Regional Banking ETF (KRE) moved up .41% over the last 5-days to close at $41.47 & the SPDR S&P Bank ETF (KBE) also moved up .41% over the last 5-days to close at $36.35. 

The CBOE Volatility Index (^VIX) closed at $14.83 & up 9.29% over the last 5-days.

As a result, the yield curve rose over the course of the week for the second straight week as the 2-yr note yield moved up 6bps to 4.94% & the 10-yr note yield moved up 23bps to 4.05%. The U.S. Dollar Index moved lower to close the week at 102.27 from 103.92 last Friday. 



As for the biotech sector, the Nasdaq Biotechnology ETF (IBB) closed at $124.38, -1.25% over the last 5-days and is now down 5.26% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,120.52, -1.39% over the last 5-days and is now down 3.04% YTD, & the SPDR S&P Biotech ETF (XBI) pulled back to closed at $81.78, -1.02% over the last 5-days, & is now down 1.47% YTD. The 52-week range is is now $72.44-$95.18. Cathie Wood’s ARK Innovation ETF (ARKK) closed at $43.73, -.14% over the last 5-days and is now up 39.98% YTD.   

However on the bright side of biotech this week, Caribou Biosciences, Inc. (Nasdaq: CRBU, $7.26, +77.94% over the last 5-days), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced that Pfizer Inc. (NYSE: PFE $35.53, -1.63% over the last 5-days), had made a $25 million equity investment in the company. Pfizer purchased 4,690,431 of Caribou common shares at a price of $5.33 per share, pursuant to the terms of a Securities Purchase Agreement dated June 29, 2023. The purchase by Pfizer closed on June 30, 2023. In conjunction with the investment, Sriram Krishnaswami, PhD, has joined Caribou’s Scientific Advisory Board.

The iShares U.S. Healthcare ETF (IYH) closed at $272.02, -1.85% over the last 5-days and is now down 4.12% YTD.  

From the world of cryptocurrency, Bitcoin (BTC) moved to $30,285.46 & down 1.60% over the course of the last 5-days at the time of the completion of this message. 

Gold prices closed at $1,932, +$6/oz over the last 5-days. Silver prices closed at $23.26, +$.31/oz over the last 5-days. 


VP Watchlist Updates

On June 26, Lantern Pharma Inc. (NASDAQ: LTRN, $5.21, +1.17% over the last 5-days) an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs in place and with a mission to transform the cost, pace, and timeline of oncology drug discovery and development, announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284’s in vitro and in vivo antitumor potency for multiple non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). The journal article titled “LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency” further supports LP-284’s development for NHL and advancement towards a first-in-human Phase 1 trial, which is anticipated for the second half of 2023. Non-Hodgkin’s lymphomas (NHL) remain one of the leading causes of cancer deaths globally and have an estimated 500,000 new cases globally, with NHL being the leading hematological malignancy in the US. Despite advances for NHL using combination and targeted therapies, nearly 20% to 40% of patients with certain subtypes still relapse after treatment. In aggressive subtypes of NHL, like MCL, nearly all patients relapse from standard-of-care (SOC) therapies. READ MORE at this link.

Lantern is an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.Lantern believes that the use of machine learning, genomics and computational methods can help accelerate the development and commercialization of small molecule-based therapies. These drugs can be targeted to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, thereby creating the potential to achieve better outcomes.Their proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. Learn more about Lantern at the VP Watchlist Page


The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices.  Shares INVO closed at $.1890, -8.70% over the last 5-days. The 52-wk range is $.15 – $1.65.

On June 27, INVO Bioscience, Inc. (NASDAQ: INVO,  $.2070), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (“IVC”) procedure it enables, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the labeling on the INVOcell device and its indication for use to provide for a 5-day incubation period. The data supporting the expanded 5-day incubation clearance demonstrated improved patient outcomes. Steve Shum, CEO of INVO stated, “This is a momentous day for INVO as the FDA has provided clearance for us to expand our labeling to cover a 5-day incubation period for INVOcell. This has been a multi-year effort to demonstrate INVOcell’s ability to improve patient outcomes using a longer incubation period, similar to conventional IVF results. We believe our ability to now communicate the improved success rates using INVOcell to patients and physicians will have a positive effect on the overall confidence and adoption of the technology going forward. The global fertility services market is a substantial, multi-billion-dollar industry and growing, with a significant underserved patient population. INVO’s commercial strategy remains focused on helping to expand affordable care to the underserved patients in need. The Company’s market approach includes the opening of dedicated “INVO Centers” offering INVOcell® and IVC procedure (three centers in North America now operational), the acquisition of existing profitable IVF clinics (signed binding agreements to acquire Wisconsin Fertility Institute), and the continued global distribution and sale of the INVOcell technology solution into existing fertility clinics. We believe the recent 510(k) clearance will help further support our overall commercial activities.”

On April 18, Maxim Group’s Analyst Jason McCarthy, Ph.D. issued a BUY rating on INVO Bioscience (INVO), a commercial-stage fertility company focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. His report is titled, “4Q Results and Outlook: Fertility Space Remains Active as INVO Expands Strategy with IVF Clinic Acquisition.” His 12-month Price Target is $3. 


On July 6, Gorilla Technology Group Inc. (NASDAQ: GRRR, $4.70, +121.70% over the last 5-days), a global provider of AI-based edge video analytics, IoT technologies, and cybersecurity, announced that it signed a contract with the Government of Egypt to implement a Smart Government Security Convergence solution. The contract, worth more than $270 million over three years, represents the largest customer win in Gorilla’s history and a notable stride in its globalization strategy, putting Gorilla on a path toward profitability by the end of 2024.


Shares of Borqs Technologies, Inc. (Nasdaq: BRQS), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, with global operations in the U.S., India, and China, closed at $.1645, -10.60% over the last 5-days.

On June 13, Borqs announced its plans to further expand into artificial intelligence, leveraging its deep IoT expertise across industries.Beyond Borqs’ current product line for water and energy reservation for smart city applications, the Company plans to accelerate development of consumer-oriented devices and solutions with artificial intelligence capabilities. Artificial Intelligence of Things (AIoT) is defined as the combination of artificial intelligence (AI) technologies with the Internet of Things (IoT) to achieve more efficient IoT operations, improve human-machine interactions and enhance data management and analytics. Borqs further plans to commercialize products that are currently targeted to be applied in e-health, sports, education, and asset protection. According to a Global Market Insights Report dated May 2023, Artificial Intelligence of Things market size was valued at over USD 9 billion in 2022 and is anticipated to grow at a CAGR of 20% between 2023 and 2032.

On May 15, Borqs reported revenues for the year ended December 31, 2022 increased 77.7% to $52.5 million compared to $29.6 million for the year ended December 31, 2021, mainly driven by increased IoT hardware sales globally and software service revenues from a global semiconductor vendor.

On May 9, Borqs announced that they have engaged Cantor Fitzgerald & Co. as its exclusive financial advisor with respect to the divestment of the Company’s ownership in Holu Hou Energy, LLC (“HHE”), a fast-growing solar energy and storage provider with unique solutions in energy sharing for the multi-dwelling residential market. Cantor Fitzgerald will conduct a sales process on behalf of Borqs with respect to its divestment in HHE and has commenced outreach to potential acquirers in May 2023. Please direct any questions regarding this sales process or prospective interest to: Hari Chandra Managing Director, Global Head of Power, Energy and Infrastructure, Cantor Fitzgerald & Co., Phone: +1 (347) 268 8636, Email: hari.chandra@cantor.com.

On April 26, Borqs Technologies published its Letter to Shareholders Regarding the Divestment of Solar Subsidiary. “Dear Shareholders of Borqs Technologies, Inc. The purpose of this letter is to help clarify the proposed divestment of our company’s ownership in Holu Hou Energy, LLC (“HHE”) and the implications that this transaction may have to Borqs and our shareholders. Why the divestment? As we have stated in prior press releases, the Committee on Foreign Investment in the United States (“CFIUS”) has notified our company by a letter dated December 13, 2022, that CFIUS has identified risks to US national security arising as a result of Borqs’s investment in HHE. CFIUS advised us that the national security risks arising as a result of Borqs’s investment transaction with HHE relate to foreign proximity to U.S. military personnel and installations through HHE’s physical access to customers and their facilities, including at off-base military housing. CFIUS therefore required Borqs and HHE to enter into a National Security Agreement with CFIUS, pursuant to which Borqs must divest its interests in HHE. Proactive steps by Borqs. Read the balance here:” 

Borqs announced that the Company has appointed Donald R. Kendall, Jr. as the sole trustee (the “Trustee”) to a divestment trust established to manage the orderly divestment of Borqs’ ownership of Holu Hou Energy, LLC, (“HHE”) as required by the Committee on Foreign Investment in the United States (“CFIUS”). Mr. Kendall has an extensive background of over four decades in investment management, including his role as the Chairperson of the Special Committee of the Board of Directors of SolarCity supervising the sale of SolarCity to Tesla, Inc. in 2016 for $2.6 billion. Mr. Kendall currently serves as the Managing Director and CEO of Kenmont Capital Partners, LP, an investment management firm with an emphasis on energy, alternative energy and transportation and General Partner of New Climate Ventures, an early-stage venture capital fund that invests in innovative early-stage startups with a focus on carbon avoidance and reduction. Mr. Kendall currently serves on the board of Talos Energy Inc. and has served on the boards of SolarCity Corporation, American Midstream Partners, LP, Stream Gas & Electric, Ltd., and Syzygy Plasmonics Inc.



Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $.9650, +3.76% over the last 5-days.

  • On June 22, InMed announced safety and efficacy results from its Phase 2 clinical trial, called 755-201-EB (the “Phase 2 Trial”), for the treatment of symptoms related to EB. The purpose of the Phase 2 Trial was to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB. All four subtypes of inherited EB, including EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome were accepted into the Phase 2 Trial. The Phase 2 Trial used a within-patient, double-blind design whereby matched index areas were randomized to INM-755 CBN cream or control cream. The Phase 2 Trial enrolled a total of 19 patients. Data from one patient were excluded from efficacy analyses due to a significant protocol deviation. Of the 18 remaining patients whose data were considered reliable for clinical review, 17 were treated for chronic non-wound itch and one patient was treated for wound-related itch. The remaining endpoints (pain, wound healing) could not be analyzed due to too few enrollees with such symptoms. Of the 18 participants assessed, chronic itch improved by a clinically meaningful amount in 12 patients (66.7%). InMed will pursue strategic partnership opportunities for INM-755 in epidermolysis bullosa (“EB”) and other itch-related skin conditions.
  • On June 1, InMed announced that results from a neurodegenerative disease study was presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research, entitled “Cannabinoids modulate cytotoxicity and neuritogenesis in Amyloid-beta-treated neuronal cells”, demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s. The research was conducted in the laboratory of Dr. Ujendra Kumar and Dr. Rishi Somvanshi of the faculty of Pharmaceutical Sciences at the University of British Columbia. Studies have shown that cannabinoids, via their endocannabinoid receptors (CB1R and CB2R) that naturally occur in the human body and brain, reduce amyloid-beta (“Aβ”) toxicity, decrease p-tau protein expression and provide neurite outgrowth, thus improving neuronal viability and function. The results presented demonstrate the anti-apoptotic effects of pCBx and its role in neuritogenesis in the cells of neuronal origin and support the role of pCBx as a potential therapeutic intervention in neurodegenerative diseases.
  • On May 31, our sister organization, Tribe Public, hosted a Presentation & Q&A Webinar Event titled “InMed Pharmaceuticals (NASDAQ: INM) Addressing The Increasing Demand For Rare Cannabinoids.” The event was co-hosted by InMed Pharmaceutical’s (NASDAQ: INM) CEO Eric A. Adams, MIBS, & BayMedica’s Jerry P. Griffin, VP, Sales and Marketing. InMed Pharmaceuticals (NASDAQ: INM, $1.34, +6.35%) is a global leader in the development, manufacturing, and commercialization of rare cannabinoids, which is developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. i.e. Alzheimer’s Disease, Glaucoma, & a rare genetic skin disease, Epidermolysis Bullosa (EB). Together with its subsidiary, BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. If you missed this event, then you may now watch the event video at the Tribe Public YouTube Channel by clicking here


Eric Adams recently stated, “In the last few months we have seen a noticeable increase in awareness, understanding and adoption of rare cannabinoids in the H&W sector, evidenced by leading companies expanding their product lines to include new formats and formulations using rare cannabinoids such as the non-psychoactive ingredient cannabichromene (“CBC”). We are encouraged by two consecutive periods of significant quarter over quarter revenue growth. We will continue to support growth in a fiscally prudent manner in this relatively nascent market, where product demand can be unpredictable. The combination of a pharmaceutical drug development pipeline, together with a revenue generating commercial operation that will be contributing to extending our cash runway makes InMed a unique company within the rare cannabinoid space.”


Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $1.19, -7.03% over the last 5-days and is up 124.53% YTD.

July 6th, Atossa announced a a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC). The goal of this research is to determine if treating TNBC with extracellular vesicles carrying the ER will convert the tumor to ER+ and render it sensitive to treatment with Selective Estrogen Receptor Modulators (SERM), including Atossa’s proprietary (Z)-endoxifen. The research project will be led by David Lyden, M.D., Ph.D., the Stavros S. Niarchos Professor in Pediatric Cardiology and Director of the Department of Pediatrics’ Physician Scientist Training Program at Weill Cornell Medicine. Dr. Lyden’s laboratory is focused on the molecular pathways activated by tumor extracellular vesicle uptake at the metastatic site and identifying potential therapeutic targets to thwart metastasis. His work has led to a new understanding of how primary tumor cells dictate their own metastases, by decoding how cancer-derived extracellular vesicles mediate intercellular communication. Most recently, Dr. Lyden has identified specific extracellular vesicle subpopulations and discovered a new subset of particles known as exomeres, which collectively have distinct functional roles in the systemic effects of cancer.

On June 28, Atossa and Quantum Leap Healthcare Collaborative™ announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial. (Z)-endoxifen is being evaluated as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit.

On June 27, Atossa announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $10 million of its common stock through December 31, 2023.

On June 21, Atossa announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,680,036) directed to enterically encapsulated endoxifen compositions formulated as a suspension. These include all liquid suspension formulations suitable for oral administration and dispersible tablets, powders, granules, pellets or sprinkles for reconstitution, which are commonly used for pediatric administration. A suspension is a heterogeneous mixture. It differs from a solution, which is a homogeneous mixture, in that the particles in a solution are much smaller and are dissolved in a solvent, therefore staying mixed together. In a suspension, the particles are large, do not dissolve, and will separate. Advantages of suspension formulations may include ease of delivery of low soluble therapeutic agents, increased bioavailability of drug dosage, controlled drug delivery and resistance to degradation. Dr. Steven Quay, Atossa’s President and Chief Executive Officer, “Our new patent covering suspension formulations is important as we continue to learn more about the potential therapeutic role of endoxifen beyond breast cancer and mammographic breast density. Suspension formulations are particularly useful in pediatric applications where drugs are often dosed by weight and delivered via powders or sprinkles mixed with food and dispersible tablets, which are easier for children to ingest compared to tablets.”

On June 12, Atossa announced that the pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa’s patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The PK run-in cohort consists of six patients, all of whom will be treated with (Z)-endoxifen at 40mg/day for four weeks. The goal of the PK run-in cohort is to determine if the 40mg dose delivers steady-state plasma concentrations (Css) between 500 – 1000 ng/mL, which are optimal to target PKCβ1 inhibition and enhance (Z)-endoxifen’s antitumor mechanism of action. Once the optimal dose of (Z)-endoxifen is determined, the Treatment Cohort will commence. Participants in the treatment cohort will receive neoadjuvant treatment for up to six months, followed by surgery. The study is expected to enroll approximately 175 patients at up to 25 sites across the United States.



Atossa’s CEO, Steven Quay, M.D., Ph.D., presented at a Tribe Public even titled “Atossa Therapeutics (NASDAQ: ATOS) Redefining Breast Cancer Prevention and Treatment” on Thursday, May 4, 2023. Dr. Quay provided an update on the clinical development of Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, which is currently being investigated in three separate Phase 2 studies. You may view the event at the following link at the Tribe Public YouTube Channel.

 

Recently, I c0-hosted a couple of our sister organization’s (Tribe Public) CEO Presentation and Q&A events that were held in Scottsdale and Peoria, AZ. The events were co-hosted by Travis Whitfill, MPH MPhil PhD(c), Cofounder and Chief Operating Officer of Azitra, Inc., a company that successfully priced their Initial Public Offering (IPO) on the Nasdaq with the ticker ‘AZTR’ recently on Friday, June 16, 2023 and closed trading today at $3.81, +2.42% over the last 5-days. Mr. Whitfill provided a presentation about Azitra’s precision dermatology platform that is augmented by an artificial intelligenceand machine learning technology that analyzes, predicts, and helps screen our library of strains for drug like molecules. You can learn more about their company today at their website https://azitrainc.com.  Thanks again for those of you that joined this event and please note that I intend on hosting the Phoenix events on the last Thursday of each month going forward with a list of evolving companies that the Tribe is seeking to meet. If you want a direct invitation going forward for Scottsdale or other cities where the Tribe is hosting events, then please let me know.  Here’s a little more info Azitra’s CEO:

Travis Whitfill (pictured above) is a serial biotech entrepreneur. He is the is the cofounder and Chief Operating Officer at Azitra. His background began in molecular biology and biochemistry after receiving scientific training at the MD Anderson Cancer Center, Duke University, and Yale University. Previously, Travis was a Partner at Bios Partners, which is biotech-focused venture capital fund. He has sat on the board of several portfolio companies, including 410 Medical, Immusoft Corporation, IN8bio (NASDAQ: INAB) and SIRPant Immunotherapeutics. He also is an Assistant Professor Adjunct in the Departments of Pediatrics and Emergency Medicine at Yale University. Mr. Whitfill has led numerous grant-funded projects, holds nearly a dozen patents, and has co-authored over 50 publications.

He was on Forbes’ 30 under 30 list (healthcare) in 2018. Mr. Whitfill received degrees from Yale University (MPH), University College London (MPhil), Dallas Baptist University (BS), and is finishing a PhD from University College London in innovation and economics.

 


Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia’s proprietary Flex-NK™ technology. These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company’s own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF). Cytovia has a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China.

On May 17, Cytovia Therapeutics R&D Team Presented Poster at ASGCT 2023 on GPC3-Targeted TALEN® Gene-Edited CAR-iNK Cell.

On Dec. 9, 2022, Cytovia announced new preclinical data for its CD38-targeted Flex-NK™ bispecific antibody at the American Society of Hematology’s 64th Annual Meeting (ASH 2022) taking place in New Orleans, LA, and virtually December 10-13th, 2022. “We’re delighted to see further progress on our CD38-targeted Flex-NK™ bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023,” commented Cytovia CEO Dr. Daniel Teper. “The data presented at ASH suggests that CYT-338, our CD38-targeted Flex-NK™ Bispecific Antibody, has a differentiated profile compared to daratumumab, the leading CD38-targeted monoclonal antibody and that CYT-338 may have the ability to overcome NK cell exhaustion and dysfunction.”  Cytovia believes that by redirecting and activating NK cells to kill myeloma cells, bispecific antibodies have the potential to offer new options for patients not responding to first lines of treatment.”



Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $6.20, +3.68% over the last 5-days. On May 2, ADT reported results for the first quarter of 2023 highlighting strong year-over-year growth in revenue; CSB and Commercial up 7% and 15%, respectively, versus prior year period, maintained record high customer retention and new record high recurring monthly revenue balance, improved capital efficiency with record revenue payback, & continued deleveraging with over $400 million debt reduction expected in 2023.


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again as we move forward!

Investing & Inspiration

  1. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  2. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  3. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  4. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  5. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  6. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  7. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  8. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  9. “Action is the foundational key to all success.” – Pablo Picasso
  10. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  11. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  12. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  13. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  14. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  15. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  16. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  17. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  18. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  19. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  20. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  21. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  22. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  23. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  24. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  25. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  26. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  27. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  28. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  29. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  30. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  31. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  32. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  33. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  34. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  35. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  36. “I want to put a ding in the universe.” – Steve Jobs

  37. “Research is creating new knowledge.” – Neil Armstrong

  38. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  39. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  40. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  41. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  42. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  43. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  44. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  45. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  46. “The best way out is always through.” – Robert Frost

  47. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  48. “Without labor nothing prospers.” – Sophocles

  49. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  50. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  51. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  52. “He who is brave is free.” – Lucius Annaeus Seneca
  53. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  54. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  55. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  56. “He who knows that enough is enough will always have enough.” – Lao Tzu

  57. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  58. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  59. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  60. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  61. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  62. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  63. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  64. “Success is dependent on effort.” – Sophocles
  65. “Nobody who ever gave his best regretted it.” – George Halas
  66. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  67. “And when I breathed, my breath was lightning.” – Black Elk
  68. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  69. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  70. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  71. “We are an impossibility in an impossible universe.” – Ray Bradbury
  72. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  73. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  74. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  75. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  76. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  77. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  78. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  79. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  80. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  81. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  82. “There is more to life than increasing its speed.” – Mahatma Gandhi
  83. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  84. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  85. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  86. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  87. “Life is too short for long-term grudges.” – Elon Musk
  88. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  89. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  90. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  91. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  92. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  93. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  94. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  95. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  96. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  97. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  98. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  99. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  100. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  101. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  102. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  103. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  104. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  105. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  106. “Delete the negative; accentuate the positive!” – Donna Karan
  107. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  108. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  109. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  110. “Everything has beauty, but not everyone sees it.” – Confucius
  111. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  112. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  113. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  114. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  115. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  116. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  117. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  118. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  119. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  120. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  121. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  122. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  123. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  124. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  125. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  126. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  127. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  128. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  129. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  130. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  131. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  132. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  133. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  134. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  135. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  136. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  137. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  138. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  139. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  140. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  141. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  142. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  143. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  144. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  145. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  146. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  147. “The secret of getting ahead is getting started.” – Mark Twain
  148. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos



Post View Count : 501